LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Xencor Inc

Fermé

SecteurSoins de santé

8.62 1.77

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.56

Max

8.69

Chiffres clés

By Trading Economics

Revenu

18M

-31M

Ventes

11M

44M

Marge bénéficiaire

-70.687

Employés

250

EBITDA

17M

-20M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+185.58% upside

Dividendes

By Dow Jones

Prochains Résultats

4 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

34M

600M

Ouverture précédente

6.85

Clôture précédente

8.62

Sentiment de l'Actualité

By Acuity

50%

50%

175 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Xencor Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 sept. 2025, 22:41 UTC

Principaux Mouvements du Marché

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sept. 2025, 16:04 UTC

Principaux Mouvements du Marché

Upexi Shares Climb on Solana Gains

12 sept. 2025, 15:03 UTC

Principaux Mouvements du Marché

Allied Gaming & Entertainment Shares Surge Following Crypto Investments

12 sept. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

12 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 sept. 2025, 20:09 UTC

Résultats

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sept. 2025, 19:23 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept. 2025, 19:16 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept. 2025, 19:03 UTC

Market Talk

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sept. 2025, 18:59 UTC

Market Talk

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sept. 2025, 18:38 UTC

Market Talk
Résultats

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sept. 2025, 18:33 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sept. 2025, 18:22 UTC

Market Talk

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sept. 2025, 16:56 UTC

Market Talk

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sept. 2025, 16:22 UTC

Résultats

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sept. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 sept. 2025, 16:19 UTC

Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

12 sept. 2025, 16:11 UTC

Résultats

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sept. 2025, 15:37 UTC

Market Talk

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sept. 2025, 15:22 UTC

Market Talk

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sept. 2025, 15:07 UTC

Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sept. 2025, 14:34 UTC

Market Talk

Russia Sanctions Put Bid Back in Oil -- Market Talk

12 sept. 2025, 14:10 UTC

Market Talk

Inflation Report Unlikely to Dissuade Canada From Rate Cut -- Market Talk

12 sept. 2025, 13:58 UTC

Market Talk

Dollar Could Rise if Fed Sounds Cautious on Rate Cuts -- Market Talk

12 sept. 2025, 13:58 UTC

Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Super Micro, Adobe, Microsoft, Figure Technology, and More -- Barrons.com

12 sept. 2025, 13:57 UTC

Résultats

AbbVie Stock Hit a Record on 'Big Win' for Blockbuster Drug. The Case for Buying In. -- Barrons.com

12 sept. 2025, 13:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 sept. 2025, 13:56 UTC

Market Talk

Canadian Dollar Faces Further Weakness Vs Non-U.S. Dollar Currencies -- Market Talk

12 sept. 2025, 13:54 UTC

Market Talk

U.S. Natural Gas Recovers Ground -- Market Talk

Comparaison

Variation de prix

Xencor Inc prévision

Objectif de Prix

By TipRanks

185.58% hausse

Prévisions sur 12 Mois

Moyen 24.56 USD  185.58%

Haut 40 USD

Bas 6 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

9

Achat

1

Maintien

1

Vente

Score Technique

By Trading Central

7.87 / 10.84Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

175 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.
help-icon Live chat